Project: Gene therapy with phosphodiesterases to treat heart failure
| Acronym | PDE4Heart (Reference Number: 14. JTC-2016_173) |
| Duration | 12/05/2017 - 11/05/2020 |
| Project Topic | In heart failure (HF) patients, the heart is unable to meet the hemodynamic needs, such as during a physical exercise or an emotional stress. The sympathetic nervous system, activated upon exercise or stress acts on the heart by the release of noradrenaline which activates beta-adrenergic receptors. Once activated, these receptors cause the production of cyclic AMP (cAMP). However, when the body demand stops, the heart returns to its normal activity by a family of enzymes called phosphodiesterases (PDEs). Thus, beta-adrenergic receptors serve as an accelerator and PDEs as a brake. In HF, the accelerator pedal is stuck to the floor and the brakes are ineffective. This project will use a new gene therapy approach to reintroduce different defective/missing types of PDEs into the heart, with the hope to prevent the associated heart rhythm disorders which are the main cause of death in HF. |
| Network | ERA-CVD |
| Call | ERA-CVD Joint Transnational Call 2016 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | INSERM UMR-S 1180 and UNIVERSITY PARIS-SUD | Coordinator | France |
| 2 | University Medical Center Hamburg-Eppendorf (UKE) | Partner | Germany |
| 3 | University of Oslo, Institute of Clinical Medicine | Partner | Finland |